These emerging therapies , Tirzepatide , represent a significant advancement in managing type 2 diabetes and potentially other conditions . These drugs are grouped as GLP-1 receptor agonists , meaning https://qasimmmvv885258.techionblog.com/41701896/semaglutide-a-deep-exploration-into-incretin-compounds